Eupraxia Pharmaceuticals Inc
TSX:EPRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Wallstreet online AG
XETRA:WSO1
|
DE |
Eupraxia Pharmaceuticals Inc
Cash from Operating Activities
Eupraxia Pharmaceuticals Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Cash from Operating Activities
-CA$28.6m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-135%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Cash from Operating Activities
-CA$8.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-98%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Operating Activities
$135.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Cash from Operating Activities
-$279.1m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
-31%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Cash from Operating Activities
-CA$9.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-97%
|
CAGR 10-Years
0%
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Cash from Operating Activities
-$99.2m
|
CAGR 3-Years
-78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Eupraxia Pharmaceuticals Inc
Glance View
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The firm's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The firm is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The firm is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.
See Also
What is Eupraxia Pharmaceuticals Inc's Cash from Operating Activities?
Cash from Operating Activities
-28.6m
CAD
Based on the financial report for Dec 31, 2025, Eupraxia Pharmaceuticals Inc's Cash from Operating Activities amounts to -28.6m CAD.
What is Eupraxia Pharmaceuticals Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-135%
Over the last year, the Cash from Operating Activities growth was 5%. The average annual Cash from Operating Activities growth rates for Eupraxia Pharmaceuticals Inc have been -15% over the past three years , -135% over the past five years .
